BCL2 and acute lymphoblastic leukemia: On the contrary, in Ph+ B-ALL cells, BCL2 and BCR-ABL1 kinase inhibition showed strong antileukemic activity and this cytotoxic effect is mediated by the BCL2 inhibitor, Venetoclax.